Baltimore based regenerative medicine company Gemstone Biotherapeutics LLC (MD, USA) has entered into a strategic partnership with Winthrop–University Hospital (NY, USA) in order to focus on developing and bringing patient-focused, evidence-based products to the advanced wound care market.
Gemstone Biotherapeutics will make use of Winthrop’s renowned wound healing specialists to refine and clinically validate its current technology. The two groups will also collaborate on projects aiming to gain insight into the wider field of wound care, leading to precision diagnostics and improved products.
“This partnership will allow Gemstone Biotherapeutics and Winthrop to greatly benefit from each other’s experience and expertise,” explained Gemstone Biotherapeutics chief executive officer George Davis. “We have a track record of taking new and promising wound care technology and transitioning it from ‘lab to bedside.’ Winthrop’s team of wound healing clinicians work 24/7 on creating better treatments for patients with chronic and serious wounds. This combination will expose those technicians to innovative new products while allowing our technology to be validated in one of the world’s best wound healing clinics.”
To kick off this collaboration, Winthrop will clinically evaluate two Gemstone Biotherapeutics technologies, including its existing biosynthetic scaffold and its angiotensin receptor blocker-based technology. The two organizations also hope to initiate studies which will identify biomarkers to bring precision medicine to advanced wound care, improving patients’ outcomes through proper treatment selection.
Written by Hannah Wilson